Pfizer launches biosimilars to Roche's 'big three' cancer dr...

Pfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at a “substantially discounted price” compared with the originators.

Roche edges closer to SMA market as risdiplam hits target in...

Roche is to begin discussions with regulators about new data from risdiplam, its developmental oral treatment for the rare muscle wasting disease spinal muscular atrophy (SMA) after support

Tumour-agnostic drugs ‘game-changing’, says NICE as it rejec...

Roche and Illumina forge genomics alliance for cancer testin...

Ligelizumab could top Xolair in chronic hives, says Novartis

Roche, big data and patient outcomes: the pharmaphorum podca...

In the first pharmaphorum podcast of 2020 Roche’s Conor Megaw talks about his company’s approach to big data and how some of its partnerships have been performing.